Evaluation of Efficacy and Toxicity of Intensified Consolidation Therapy in AML Patients greater than or equal to 60 Years.

Trial Profile

Evaluation of Efficacy and Toxicity of Intensified Consolidation Therapy in AML Patients greater than or equal to 60 Years.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 25 Oct 2012

At a glance

  • Drugs Pegfilgrastim (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top